Swiss National Bank Purchases 16,800 Shares of Biohaven Ltd. (NYSE:BHVN)

Swiss National Bank lifted its position in Biohaven Ltd. (NYSE:BHVN - Free Report) by 12.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 154,800 shares of the company's stock after buying an additional 16,800 shares during the period. Swiss National Bank owned approximately 0.15% of Biohaven worth $5,782,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of BHVN. Spire Wealth Management bought a new position in Biohaven in the fourth quarter worth approximately $56,000. Amalgamated Bank increased its stake in shares of Biohaven by 21.9% in the 4th quarter. Amalgamated Bank now owns 2,929 shares of the company's stock worth $109,000 after purchasing an additional 527 shares in the last quarter. US Bancorp DE raised its holdings in Biohaven by 36.7% in the 4th quarter. US Bancorp DE now owns 2,971 shares of the company's stock worth $111,000 after purchasing an additional 798 shares during the period. KBC Group NV lifted its position in Biohaven by 50.1% during the fourth quarter. KBC Group NV now owns 3,377 shares of the company's stock valued at $126,000 after purchasing an additional 1,127 shares in the last quarter. Finally, Capstone Investment Advisors LLC purchased a new position in Biohaven during the third quarter valued at $250,000. Institutional investors own 88.78% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Deutsche Bank Aktiengesellschaft set a $60.00 price objective on Biohaven and gave the stock a "buy" rating in a research note on Thursday, March 20th. JPMorgan Chase & Co. lowered their price target on shares of Biohaven from $72.00 to $68.00 and set an "overweight" rating on the stock in a report on Wednesday, March 5th. Morgan Stanley dropped their price target on shares of Biohaven from $69.00 to $63.00 and set an "overweight" rating for the company in a research report on Friday, March 7th. Cantor Fitzgerald restated an "overweight" rating on shares of Biohaven in a research report on Tuesday, December 17th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $54.00 target price on shares of Biohaven in a report on Tuesday, March 4th. Fourteen equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $62.77.

Remove Ads

Insiders Place Their Bets

In related news, Director John W. Childs bought 32,700 shares of the company's stock in a transaction dated Tuesday, March 4th. The stock was purchased at an average price of $30.47 per share, for a total transaction of $996,369.00. Following the acquisition, the director now owns 2,320,571 shares in the company, valued at $70,707,798.37. This trade represents a 1.43 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 16.00% of the company's stock.

Biohaven Stock Down 1.8 %

Biohaven stock traded down $0.51 during midday trading on Thursday, reaching $28.35. 603,583 shares of the stock traded hands, compared to its average volume of 969,520. The stock has a market cap of $2.89 billion, a P/E ratio of -3.03 and a beta of 1.27. The stock's fifty day moving average is $35.50 and its 200-day moving average is $41.47. Biohaven Ltd. has a 12 month low of $26.80 and a 12 month high of $57.02.

Biohaven (NYSE:BHVN - Get Free Report) last posted its earnings results on Monday, March 3rd. The company reported ($1.85) EPS for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.29). On average, equities analysts predict that Biohaven Ltd. will post -8.9 EPS for the current fiscal year.

Biohaven Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.